AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04522492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life promotion
Description: 2 videos about quality of life promotion will be send to patients in the active control arm. In the first week, the videos will consist in: social support techniques and sleep hygiene. After one week, 2 another videos will be send, consisting in: guide about healthy diet and about physical exercise.
Study NCT02086019 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Conservative Arm
Description: crossover to angiogram only if predefined criteria met
Study NCT02086019 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Invasive Arm
Description: angiogram with PCI or CABG revascularisation if appropriate
Study NCT01892488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Description: Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD.
Study NCT01892488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD
Study NCT03496701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: contact lens
Study NCT03496701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control lens
Description: contact lens
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m\^2 intravenously on day 1,then 250 mg/m\^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m\^2 intravenously every week concurrent with radiotherapy.
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m\^2 intravenously every week concurrent with radiotherapy.
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75mg/m\^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
Study NCT02633176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m\^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
Study NCT02633176 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
Study NCT02633176 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
Study NCT02278913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Bolus (Glargine and Glulisine)
Description: Glargine daily + Glulisine before meals
Study NCT02278913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Insulin
Description: NPH twice a day + Regular insulin before meals
Study NCT01264939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Study NCT01722695 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dialyzer comparison
Description: Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization.
Study NCT01264939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study NCT01264939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
Description: Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
Study NCT04078022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a strain 2457T Challenge Agent
Description: Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
Study NCT01264939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
Description: Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
Study NCT01264939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
Study NCT01264939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
Study NCT04348851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver problem-solving
Description: Registered nurses will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue
Study NCT00424853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin followed by gemcitabine
Description: docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
Study NCT01576055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGRIS Vascular Stent
Description: Implant
Study NCT01576055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD LifeStent
Description: Implant
Study NCT03048032 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
Study NCT03048032 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiography exam
Description: A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
Study NCT01495182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fiber
Description: A proprietary fiber will be given to subjects
Study NCT01495182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: A proprietary fiber will be given to subjects
Study NCT04348851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: The RNs will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare
Study NCT03557021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV Drug resistance testing
Description: HIV Drug resistance testing by HIV pro DNA sanger sequencing
Study NCT00326690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Egg Device
Study NCT03557021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HIV Drug resistance testing
Description: HIV Drug resistance testing by HIV pro DNA sanger sequencing
Study NCT03534037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Description: Febuxostat 40 mg orally per day plus dietary control only
Study NCT03534037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzbromarone 50mg
Description: Benzbromarone 50mg orally per day plus dietary control only
Study NCT03534037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Dietary control only
Study NCT06379334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine test
Description: Urine samples were collected and their proteomes were analyzed via liquid chromatography with tandem mass spectrometry using data-dependent acquisition or parallel reaction monitoring.
Study NCT03623230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Femoral Nerve Block
Description: Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
Study NCT00363961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: resistance exercise vs sham comparison
Study NCT00363961 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Resistance exercise
Description: resistance exercise vs sham comparison
Study NCT00058461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00058461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00058461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00058461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00058461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00058461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT
Study NCT00058461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT
Study NCT00058461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03709563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutraceutical Supplement
Description: Standardized Botanicals. Take 4 capsules by mouth daily with a meal
Study NCT03623230 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dressing
Description: Only dressing will be applied to related area to protect blindness between groups
Study NCT03709563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Take 4 capsules by mouth daily with a meal
Study NCT01955616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Study NCT03623230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Perineural Injection
Study NCT03623230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.125% Injectable Solution
Description: Perineural Injection
Study NCT02767921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT02767921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02767921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo robotic-assisted radical cystectomy
Study NCT02767921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study NCT02767921 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo robotic-assisted radical or partial nephrectomy
Study NCT01278095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 solid dispersion
Description: solid dispersion capsules, 50 mg, single dose
Study NCT01278095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0555 nanosuspension
Description: Nanosuspension, 50 mg, single dose
Study NCT02100761 — intervention group
Intervention type: DRUG
Intervention: Voriconazole
Description: Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance \<50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
Study NCT03549793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Therapy
Description: the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
Study NCT03549793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercises without dance
Description: the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
Study NCT01464905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NU100
Description: 0.25 mg SQ, every other day for 12 months
Study NCT01464905 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL SQ, every other day for 4 months
Study NCT01464905 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rhIFN beta-1b
Description: 0.25 mg SQ, every other day for 12 months
Study NCT00871507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 Dose 1
Description: Liquid suspension/solution of JNJ-38431055 administered as a single dose
Study NCT00871507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Capsule containing 100 mg of sitagliptin administered as a single dose.
Study NCT00871507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension/solution and Placebo capsule administered as single doses
Study NCT00871507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38431055 Dose 2
Description: Liquid suspension/solution of JNJ-38431055 administered as a single dose
Study NCT00627952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 10 mg
Description: amlodipine 10 mg once daily
Study NCT00627952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manidipine 20 mg
Description: manidipine 20 mg once daily
Study NCT00627952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine 5 mg + delapril 30 mg
Description: amlodipine 5 mg + delapril 30 mg once daily
Study NCT00627952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: manidipine 10 mg + delapril 30 mg
Description: manidipine 10 mg + delapril 30 mg once daily
Study NCT02417493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation of epinephrine self-injection
Study NCT01006603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg, oral tablet, once daily
Study NCT01006603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
Study NCT03703401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hysterosalpingo-contrast-sonogram
Description: A contrast ultrasound scan to examine fallopian tube pathology and blockage
Study NCT00613067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: * Start with escitalopram 10mg~* According to patient's symptoms, stay on 10mg or increase up to 20mg~* Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~* Length of washout period will be at least 2 weeks for any psychotropic drugs
Study NCT02814500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R212
Description: Investigational product is prescribed to all of randomized subjects
Study NCT04395222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen
Study NCT01955616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04395222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
Study NCT00936520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR 1118 0.1%
Description: Daily eye drops (twice daily, \~50 microliter \[uL\] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study NCT00936520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR 1118 1.0%
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study NCT05461443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Study NCT05461443 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Study NCT02814500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Investigational product is prescribed to all of randomized subjects
Study NCT02814500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Investigational product is prescribed to all of randomized subjects
Study NCT00936520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR 1118 5.0%
Description: Daily eye drops (twice daily, \~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
Study NCT03652194 — intervention group
Intervention type: OTHER
Intervention: in vitro evaluation of epithelial immune response during C. glabrata infection
Description: 1. study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~2. study of protein expression by the Western-Blot method